1. Medtech Insight
  2. >>Business
  3. >>R&D
  4. >>Clinical Trials

Research In Brief

Data reports on obesity devices, bone density screening and more.

Roux-en-Y gastric bypass is associated with greater weight loss and results in better correction of some comorbidities compared to gastric banding, Swiss investigators concluded on Jan. 16 in the Archives of Surgery. The data come from a 442-patient case-matched study, where half the patients underwent laparoscopic banding and half the patients had bypass. Patients were followed for six years. Patients who received the more invasive bypass procedure experienced a higher early-complication rate. But the longer-term complication and reoperation rates were higher with gastric banding. Gastric banding was performed with either Allergan’s Lap-Band or Johnson & Johnson/Ethicon Endo-Surgery’s Realize (marketed in Europe as the Swedish Adjustable Gastric Band.

Nine months into its Orion trial, Boston Scientific’s Epic self-expanding nitinol peripheral artery stent system has met its primary endpoint...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Digital Health Roundup: Synchron Syncs With Apple, Ketryx’s AI Agents, AdvaMed’s AI RoadMap

 
• By Marion Webb, Brian Bossetta, Natasha Barrow, Elizabeth Orr, and Shubham Singh

In this week's Digital Health Roundup, MedTech Insight's Shubham Singh explores how Ketryx's launch of validated AI agents could reshape compliance automation in medtech. Marion Webb highlights news from BCI makers Synchron, Axoft and Subsense. Elizabeth Orr discusses AI advances at the FDA.

Guardant’s Multi-Cancer Detection Test Granted FDA Breakthrough Device Designation

 
• By Natasha Barrow

Guardant Health’s methylation-based blood test – Shield MCD – showed a specificity of 98.6% and sensitivity of 75% across eight cancer types in its clinical validation data presented at ASCO.

Abbott Announces FDA Approval Of Tendyne Transcatheter Mitral Valve Replacement System

 
• By Marion Webb

Abbott received the US FDA nod for its Tendyne system, offering a minimally invasive alternative to replace the valves of patients with severe mitral valve disease who are at risk for open-heart surgery.

Cardiosense Advances Noninvasive Heart Monitoring With Final Validation Study

 
• By Marion Webb

Cardiosense has launched a nationwide clinical study, SEISMIC-HF II, to validate its non-invasive, AI-powered technology for monitoring heart failure. The data will be used to file for US regulatory clearance of the Cardiosense heart failure monitoring platform.

More from R&D